On June 4, 2024, Three Clover Biopharmaceutical Co., Ltd. ('Three Clover Bio-B') submitted the latest monthly securities variation report to Hong Kong Exchanges and Clearing Limited, reporting the shareholding changes as of May 31, 2024. The report shows that the company's statutory/registered capital and issued shares remained unchanged during the reporting period, with a total of 2,000,000,000 shares, a face value of US$0.0001 per share, and a total amount of US$200,000. In addition, the company's share option plan includes the pre- and post-listing stock option plans, with the pre-listing stock option plan approved on April 15, 2021 and the post-listing stock option plan approved on September 26, 2021. During the reporting period, the closing balance of share options for the pre-listing...Show More

On June 4, 2024, Three Clover Biopharmaceutical Co., Ltd. ('Three Clover Bio-B') submitted the latest monthly securities variation report to Hong Kong Exchanges and Clearing Limited, reporting the shareholding changes as of May 31, 2024. The report shows that the company's statutory/registered capital and issued shares remained unchanged during the reporting period, with a total of 2,000,000,000 shares, a face value of US$0.0001 per share, and a total amount of US$200,000. In addition, the company's share option plan includes the pre- and post-listing stock option plans, with the pre-listing stock option plan approved on April 15, 2021 and the post-listing stock option plan approved on September 26, 2021. During the reporting period, the closing balance of share options for the pre-listing stock option plan was 1,854,317 shares, while the closing balance of share options for the post-listing stock option plan was 28,462,004 shares, but no options were exercised to issue new shares this month. The report also confirms that all securities issuances have been approved by the board of directors and comply with the relevant requirements of the Listing Rules of Hong Kong Exchanges and Clearing Limited.